Monitoring tumor-derived cell-free DNA in patients with solid tumors

Clinical perspectives and research opportunities

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence.This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

Original languageEnglish
Pages (from-to)648-655
Number of pages8
JournalCancer Treatment Reviews
Volume40
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

DNA
Research
Neoplasms
Biopsy
Body Fluids
Epigenomics
Mental Competency
Disease Progression
Biomarkers
Genotype
Genome
Neoplasm Metastasis
Pressure
Serum
Therapeutics

Keywords

  • Breast cancer
  • Cell free DNA
  • Circulating nucleic acids
  • Colorectal cancer
  • Lung cancer
  • Ovarian cancer
  • Plasma/serum DNA
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{9e8f3882740a46eaadf93acb63b5a75d,
title = "Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities",
abstract = "Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The {"}liquid biopsy{"} provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence.This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.",
keywords = "Breast cancer, Cell free DNA, Circulating nucleic acids, Colorectal cancer, Lung cancer, Ovarian cancer, Plasma/serum DNA, Prostate cancer",
author = "Angela Esposito and Alberto Bardelli and Carmen Criscitiello and Nicoletta Colombo and Lucia Gelao and Luca Fumagalli and Ida Minchella and Marzia Locatelli and Aron Goldhirsch and Giuseppe Curigliano",
year = "2014",
doi = "10.1016/j.ctrv.2013.10.003",
language = "English",
volume = "40",
pages = "648--655",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Monitoring tumor-derived cell-free DNA in patients with solid tumors

T2 - Clinical perspectives and research opportunities

AU - Esposito, Angela

AU - Bardelli, Alberto

AU - Criscitiello, Carmen

AU - Colombo, Nicoletta

AU - Gelao, Lucia

AU - Fumagalli, Luca

AU - Minchella, Ida

AU - Locatelli, Marzia

AU - Goldhirsch, Aron

AU - Curigliano, Giuseppe

PY - 2014

Y1 - 2014

N2 - Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence.This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

AB - Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence.This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

KW - Breast cancer

KW - Cell free DNA

KW - Circulating nucleic acids

KW - Colorectal cancer

KW - Lung cancer

KW - Ovarian cancer

KW - Plasma/serum DNA

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84898458573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898458573&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2013.10.003

DO - 10.1016/j.ctrv.2013.10.003

M3 - Article

VL - 40

SP - 648

EP - 655

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 5

ER -